Liberal Democratic Party (LDP) leader Fumio Kishida was sworn in as Japan’s 100th prime minister. While a major focus is on how he will embody his centerpiece policy proposals made during the LDP campaign, another key topic is how the…
REGULATORY
MHLW Eyes Booster Shots for Healthcare Workers from December
While no official decision has been made for the scope of people who will receive the third dose of COVID-19 vaccines, the Ministry of Health, Labor and Welfare (MHLW) is pushing initiatives with an eye to starting booster shots for…
To read the full story
Related Article
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- COVID-19 Expert Omi Urges Govt to Consider Booster Shots
September 9, 2021
REGULATORY
- PMDA Issues Guidance on COVID-19 Vaccines’ Immunogenicity Assessment for Non-Placebo-Controlled Trials
October 25, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- MHLW Proposes Further Measures to Promote Generics in Basic Plan for FY2022 Reimbursement Reform
October 25, 2021
- MHLW Panel OKs 81 More COVID-19 Vaccine Health Damage Claims
October 25, 2021
- Tecentriq under PMDA Safety Review for Cholangitis Sclerosing
October 25, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…